Peptides DB
Research-centric peptide and protocol reference hub
Study 17 of 17Vipivotide literatureJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · Review · Phase 32023

Lutetium Lu 177 vipivotide tetraxetan: A literature review.

Lutetium Lu 177 vipivotide tetraxetan shows promise for treating mCRPC, but ongoing studies are needed to clarify its effectiveness in earlier stages of the disease.

Read at Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy PractitionersAdd to compare

Where it sits

this study against the rest of the vipivotide corpus
3
Preclinical
10
Observational
0
Open-label
2
Randomised
2
Reviews · this one

Summary and findings

This literature review evaluates the pharmacology, pharmacokinetics, and safety of lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC). It reports on findings from two phase III clinical trials where the treatment was administered at a dose of 7.4 GBq intravenously every 6 weeks for up to 6 doses. The review indicates that the treatment is generally well tolerated with specific adverse effects noted.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.Phase 32023

Abstract

The authors’ words, as Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners supplied them

To review pharmacology, pharmacokinetics, therapeutic use, product safety/description and perspectives on use of lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC). <b>Data sources:</b> A literature search was conducted using PubMed/Dynamed (October 2013-May 2025), limited to English language, humans, clinical trials, case reports, and guidelines. <b>Data summary:</b> Lutetium Lu 177 vipivotide tetraxetan is comprised of the beta-emitting radioisotope lutetium Lu-177 linked to a peptide, vipivotide tetraxetan, which binds to cells expressing prostate-specific membrane antigen (PSMA), resulting in cell death from the radiation. Kidney excretion may result in increased renal toxicity in patients with reduced renal function. Based on 2 phase III clinical trials, lutetium Lu 177 vipivotide tetraxetan 7.4 GBq administered intravenously every 6 weeks for up to 6 doses is effective in patients with mCRPC and PSMA-positive metastases after progressing on an androgen receptor pathway inhibitor and docetaxel therapy or an androgen receptor pathway inhibitor alone, by significantly improving radiographic progression-free survival. It is generally well tolerated, with asthenia/fatigue, dry mouth, mild nausea and low-grade anemia most commonly occurring. Severe adverse drug reactions are uncommon. It should only be administered by trained personnel in a designated clinical setting with existing radiation safety protocols. Patients must limit close contact, use precautions with using the bathroom and other daily activities in days following treatment. Patient education is necessary to ensure safe daily practices. Several ongoing trials are evaluating lutetium Lu 177 vipivotide tetraxetan in combination with other anticancer agents for treatment of mCRPC, using different dosing strategies, or in other settings (metastatic castration-sensitive prostate cancer and early-stage prostate cancer). <b>Conclusion:</b> Lutetium Lu 177 vipivotide tetraxetan is an effective and well tolerated treatment for patients with mCRPC, PSMA-positive metastases after progressing on an androgen receptor pathway inhibitor ± docetaxel. Ongoing studies evaluating its use in earlier disease stages and with different dosing strategies, will better define the role of this therapy in the treatment of prostate cancer.

Background

The paper addresses the clinical question of the efficacy and safety of lutetium Lu 177 vipivotide tetraxetan for treating metastatic castration-resistant prostate cancer (mCRPC). Prior knowledge indicated that this treatment targets cells expressing prostate-specific membrane antigen (PSMA) and utilizes a beta-emitting radioisotope. This review is significant as it compiles findings from multiple studies to inform clinical practice regarding this therapy.

Methods

A literature search was conducted using PubMed/Dynamed from October 2013 to May 2025, focusing on English-language studies involving humans, clinical trials, case reports, and guidelines. The review summarizes data from two phase III clinical trials assessing the treatment's effectiveness and safety profile.

Results

The review indicates that lutetium Lu 177 vipivotide tetraxetan significantly improves radiographic progression-free survival in patients with mCRPC and PSMA-positive metastases. Specific numeric outcomes related to survival rates or statistical significance were not detailed in the abstract.

Interpretation

While the findings suggest that lutetium Lu 177 vipivotide tetraxetan is effective, the lack of detailed statistical results limits the ability to assess the clinical significance of the observed effects. The review highlights the need for ongoing studies to further evaluate the treatment's role in earlier disease stages and with varying dosing strategies. Confounding factors include the reliance on existing literature without original data analysis.

Key findings

  • 7.4 GBq administered intravenously every 6 weeks for up to 6 doses.
  • Significantly improving radiographic progression-free survival in patients with mCRPC and PSMA-positive metastases.
  • Most common adverse effects include asthenia/fatigue, dry mouth, mild nausea, and low-grade anemia.
  • Severe adverse drug reactions are uncommon.

Limitations

  • Not reported in abstract.
  • No specific numeric outcomes or detailed statistical analyses provided.
  • Review based on existing literature without original data.

Elsewhere in the Vipivotide corpus

BThrombotic Microangiopathy in Patients Treated with &lt;sup&gt;177&lt;/sup&gt;Lu-PSMA Combination Therapies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · n=766 · Cumulative renal absorbed dose ranged from 38.6 to 65.3 Gy.HumanDGuideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.BJU international · 2026 · 7.4 GBq every 6 weeks for up to six cycles.reviewCIdentification and functional verification of resistance genes against Lily bulb virus-1 (LbV-1) in Lilium: Insight from sRNA sequencing and transcriptomic profiling.Plant science : an international journal of experimental plant biology · 2026 · Infection rate of up to 45% in progeny plants.In vitroDClinical and economic outcomes of cabazitaxel versus Lu-PSMA in mCRPC: a US perspective.Journal of medical economics · 2026 · 66% PSA response for Lu-PSMA vs 37% for cabazitaxel, p<0.0001.reviewBTreatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC).Clinical genitourinary cancer · 2026 · n=743 · Median overall survival was 8.0 months (95% CI: 6.8-11.5).HumanBPostmarketing safety of [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system.Expert opinion on drug safety · 2025 · n=870 · 870 adverse event reports associated with [177Lu]Lu-PSMA-617 in prostate cancer patients.review